Gsk (GSK) Equity Income (2009 - 2022)

Gsk (GSK) has 14 years of Equity Income data on file, last reported at -$2.3 million in Q4 2022.

• For the quarter ending Q4 2022, Equity Income fell 105.44% year-over-year to -$2.3 million; the trailing twelve-month figure through Dec 2022 stood at -$7.4 million (down 108.05% YoY), and the FY2025 full-year result was $1.3 million, up 134.69% from the prior year.
• Equity Income was -$2.3 million for Q4 2022 at Gsk, down from -$1.2 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $43.1 million in Q4 2021 to a low of -$74.2 million in Q1 2019.
• A 5-year average of -$3.9 million and a median of -$1.3 million in 2022 frame the typical range for Equity Income.
• Across the five-year window, Equity Income tumbled 581.43% in 2019 and soared 558.52% in 2020, its largest moves.
• Gsk's Equity Income stood at $14.2 million in 2018, then sank by 581.43% to -$68.1 million in 2019, then jumped by 45.74% to -$37.0 million in 2020, then jumped by 216.67% to $43.1 million in 2021, then sank by 105.44% to -$2.3 million in 2022.
• Per Business Quant data, the three most recent Equity Income figures were -$2.3 million in Q4 2022, -$1.2 million in Q3 2022, and -$2.5 million in Q2 2022.